BofA warns Fed risks policy mistake with early rate cuts
SEATTLE—Graham Juan, the Chief Financial Officer of Perspective Therapeutics, Inc. (NYSE:CATX), recently acquired a significant amount of the company’s common stock. According to a recent filing, Juan purchased 33,333 shares on March 28, 2025, at a weighted average price of approximately $2.25 per share. This acquisition represents a total investment of $74,945. The purchase comes as the stock trades near its 52-week low, having declined over 83% in the past year. InvestingPro analysis suggests the stock is currently undervalued.
The shares were bought in multiple transactions, with prices ranging from $2.19 to $2.30. Following this purchase, Juan’s total direct ownership of Perspective Therapeutics stock increased to 35,354 shares. Track insider transactions and access comprehensive analysis with InvestingPro’s detailed research reports, available for over 1,400 US stocks.
Perspective Therapeutics, formerly known as IsoRay , Inc., is engaged in the development and commercialization of medical instruments and apparatus. The company’s headquarters are located in Seattle, Washington. With a market capitalization of $144.4 million, the company maintains a strong liquidity position with a current ratio of 12.68 and minimal debt-to-equity of 0.01.
In other recent news, Perspective Therapeutics Inc has reported significant developments in its financial and clinical operations. The company disclosed a year-ending cash balance of $227 million, which is expected to support its operations until late 2026, providing financial stability crucial for ongoing research and development. Oppenheimer analysts maintained an Outperform rating with a $16 price target, reflecting confidence in the company’s financial health and therapeutic programs. Meanwhile, Scotiabank (TSX:BNS) initiated coverage with a Sector Outperform rating and a $15 price target, highlighting optimism about Perspective Therapeutics’ potential amidst skepticism about its neuroendocrine tumor program.
Lucid (NASDAQ:LCID) Capital Markets raised its price target to $20, citing new data from the VMT-α-NET (Pb-212 radioligand) study as evidence of the drug’s potential to be best-in-class. This increase in target price follows a presentation at the ASCO GI 2025 conference, which addressed previous concerns and improved investor sentiment. Perspective Therapeutics’ status as an independent player in the radiopharmaceutical space and its promising pipeline developments have contributed to a positive outlook from analysts. The company’s ongoing clinical trials, regulatory discussions, and financial backing remain focal points for investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.